TCI Wealth Advisors’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-710
Closed -$15.4K 639
2023
Q1
$15.4K Hold
710
﹤0.01% 842
2022
Q4
$14.4K Buy
710
+156
+28% +$3.91K ﹤0.01% 849
2022
Q3
$14K Hold
554
﹤0.01% 822
2022
Q2
$13K Buy
554
+22
+4% +$479 ﹤0.01% 842
2022
Q1
$12K Hold
532
﹤0.01% 965
2021
Q4
$11K Buy
532
+82
+18% +$1.66K ﹤0.01% 1076
2021
Q3
$9K Buy
450
+222
+97% +$4.65K ﹤0.01% 1151
2021
Q2
$5K Sell
228
-77
-25% -$1.71K ﹤0.01% 1416
2021
Q1
$7K Buy
305
+195
+177% +$5.21K ﹤0.01% 1040
2020
Q4
$3K Hold
110
﹤0.01% 1070
2020
Q3
$2K Hold
110
﹤0.01% 1086
2020
Q2
$2K Hold
110
﹤0.01% 1039
2020
Q1
$1K Buy
110
+35
+47% +$433 ﹤0.01% 1213
2019
Q4
$1K Hold
75
﹤0.01% 1309
2019
Q3
$1K Hold
75
﹤0.01% 1253
2019
Q2
$1K Hold
75
﹤0.01% 1168
2019
Q1
$1K Sell
75
-52
-41% -$646 ﹤0.01% 1181
2018
Q4
$2K Buy
127
+52
+69% +$687 ﹤0.01% 972
2018
Q3
$1K Hold
75
﹤0.01% 1185
2018
Q2
$1K Sell
75
-48
-39% -$835 ﹤0.01% 1267
2018
Q1
$2K Buy
123
+48
+64% +$889 ﹤0.01% 949
2017
Q4
$1K Hold
75
﹤0.01% 1160
2017
Q3
$1K Hold
75
﹤0.01% 1083
2017
Q2
$1K Hold
75
﹤0.01% 1110
2017
Q1
$1K Buy
+75
New +$659 ﹤0.01% 1065

Other funds holding CORT

TCI Wealth Advisors's CORT Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Corcept Therapeutics (CORT) in Q2 2023, closing a stake of 710 shares — an estimated $15.4K sold.

TCI Wealth Advisors first reported a position in CORT in Q1 2017 and held it in 25 quarters. The position peaked at $15.4K in Q1 2023. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Corcept Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 710 Corcept Therapeutics shares in Q2 2023, an estimated $15.4K.
  • TCI Wealth Advisors first reported a position in Corcept Therapeutics in Q1 2017 and held it in 25 quarters.
  • TCI Wealth Advisors's Corcept Therapeutics position peaked at $15.4K in Q1 2023.
  • 224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.